Print

FDA grants expanded access to an investigational drug for pancreatic cancer

https://www.facingourrisk.org/XRAY/expanded-access-to-daraxonrasib-pancreatic-cancer

Full article: https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug

The U.S. Food and Drug Administration (FDA) granted expanded access to the investigational drug daraxonrasib for people with previously treated pancreatic cancer. This allows more access to the drug outside of a clinical trial, even though it has not yet been approved by the FDA. (posted 5/29/2026)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.